Exploratory analysis of serum Krebs von den Lungen-6, blood gas analysis & Brixia score in determining COVID-19 severity & mortality
- PMID: 39382415
- PMCID: PMC11463251
- DOI: 10.25259/ijmr_2516_22
Exploratory analysis of serum Krebs von den Lungen-6, blood gas analysis & Brixia score in determining COVID-19 severity & mortality
Abstract
Background & objectives Krebs von den Lungen-6 (KL-6) is primarily expressed by the damaged type II pneumocytes. In this context, the relationship of KL-6 with blood gas analysis (BGA) parameters and Brixia score is still limitedly discussed. This study aims to analyze the correlation of KL-6, BGA and Brixia scores to the severity and mortality of COVID-19. Methods A cross-sectional study was conducted in adult COVID-19 positive individuals at Universitas Airlangga Hospital, Surabaya, East Java, Indonesia, from March to August 2021. KL-6, BGA, and Brixia scores were compared according to severity (severe vs. non-severe) and mortality (non-survivor vs. survivor). The receiver operating characteristic (ROC) analysis was also performed to define the optimal cut-off, sensitivity, as well as the specificity of KL-6, BGA and Brixia scores to determine the COVID-19 severity and mortality. Results Total 35 severe and 20 non-severe COVID-19 positive individuals were enrolled in this study. Of those, there were 22 non-survivors. No significant difference in serum KL-6 levels was observed in the severity and mortality groups. KL-6 and HCO3- had positive correlation in the severe group (r=0.37). KL-6 and Brixia scores showed a significant negative correlation among COVID-19 positive individuals (r=-0.283; P=0.036). KL-6 and Brixia scores together served as the best severity markers in the current study [AUC 0.809 (0.697-0.920); Sn/Sp=0.686/0.900)], followed by KL-6 and P/F ratio [AUC 0.800 (0.637-0.963); Sn/Sp=0.971/0.750]. Interpretation & conclusions The findings of this study suggest that KL-6 has the potential to be a useful adjunct laboratory parameter to the BGA and Brixia score representing COVID-19 severity and mortality.
Keywords: Biomarker; COVID-19; KL-6; SARS-CoV-2-severity; blood gas analysis; brixia; mortality.
Figures



Similar articles
-
An in-depth investigation of serum Krebs von den Lungen-6 and other biomarkers in COVID-19 severity and mortality.Monaldi Arch Chest Dis. 2024 Jul 26. doi: 10.4081/monaldi.2024.2848. Online ahead of print. Monaldi Arch Chest Dis. 2024. PMID: 39077858
-
Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China.Biosci Trends. 2020 Sep 21;14(4):290-296. doi: 10.5582/bst.2020.03197. Epub 2020 Jun 21. Biosci Trends. 2020. PMID: 32565512
-
Serum KL-6 concentrations as a novel biomarker of severe COVID-19.J Med Virol. 2020 Oct;92(10):2216-2220. doi: 10.1002/jmv.26087. Epub 2020 Jun 9. J Med Virol. 2020. PMID: 32470148 Free PMC article.
-
Krebs von den Lungen-6 (KL-6) as a clinical marker for severe COVID-19: A systematic review and meta-analyses.Virology. 2022 Jan;566:106-113. doi: 10.1016/j.virol.2021.11.006. Epub 2021 Dec 4. Virology. 2022. PMID: 34896901 Free PMC article.
-
Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.Iran Biomed J. 2021 Nov 1;25(6):381-9. doi: 10.52547/ibj.25.6.381. Iran Biomed J. 2021. PMID: 34641641 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous